Investors should monitor the upcoming spin-off execution and Phase 1b data readouts for ANB033 in 2026–2027. The strong Jemperli commercial trajectory supports near-term royalty growth, while the separation creates optionality between a pure-play royalty vehicle and a clinical-stage biotech.
Price Chart
Executive Summary
AnaptysBio reported strong Q4 and full-year 2025 financial results driven by a surge in Jemperli royalties and milestones from GSK, including a $75M milestone payment. Collaboration revenue more than doubled, and the company confirmed progress toward a Q2 2026 spin-off of its biopharma assets into First Tracks Biotherapeutics. Despite a net loss for the year, cash remains robust at $311.6M, and the royalty outlook is bullish with >$390M in annualized royalties expected by 2029.
Key Financial Metrics
Key Facts
- Collaboration revenue was $108.2M (Q4) and $234.6M (full year 2025), up from $43.1M and $91.3M in 2024.
- Jemperli achieved $1B in global sales in Nov 2025, triggering a $75M milestone payment to Anaptys.
- Jemperli royalties grew 103% YoY to $96.0M for the year, with a $1.4B annualized run rate in Q4.
- Anaptys expects >$390M in annualized Jemperli royalties by 2029 at GSK's peak sales guidance of >$2.7B.
- Cash and investments totaled $311.6M as of Dec 31, 2025, down from $420.8M due to operating use and share repurchases.
- Company repurchased 11.2% of shares outstanding ($68.6M) under its $175M buyback program.
- Spin-off of biopharma operations into First Tracks Biotherapeutics (TRAX) on track for Q2 2026, potentially as early as late April.
- Phase 1b trials for ANB033 in celiac disease and eosinophilic esophagitis ongoing, with data expected in Q4 2026 and 2027, respectively.
Financial Impact
Revenue more than doubled YoY to $234.6M; Jemperli royalties now on a $1.4B annualized run rate, implying significant future royalty growth. Expected peak annual royalties >$390M.
Risk Factors
- Spin-off timing or structure could change, creating uncertainty.
- Clinical development risks for ANB033, rosnilimab, and ANB101 remain high.
- Future royalty payments depend on GSK achieving peak sales guidance, which is not guaranteed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248938 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | Institutional Cluster | $56.02 $53.87 | ▼ −3.84% | ▼ −2.09% | $48.53 (−13.37%) |
Jun 29, 2026 13w ago | 144 | $67.50 $53.61 | ▲ +20.58% | ▲ +19.55% | $48.53 (+28.10%) |
Jun 29, 2026 13w ago | DEFA14A | $67.50 $53.61 | ▼ −20.58% | ▼ −19.55% | $48.53 (−28.10%) |
Jun 26, 2026 13w ago | 144 | $65.97 $54.15 | ▲ +17.92% | ▲ +17.64% | $48.53 (+26.44%) |
Jun 22, 2026 14w ago | 8-K | $59.43 $50.29 | ▼ −15.38% | ▼ −16.54% | $48.53 (−18.34%) |
Jun 17, 2026 15w ago | 144 | $57.51 $54.15 | ▲ +5.84% | ▲ +6.38% | $48.53 (+15.61%) |
Jun 15, 2026 15w ago | 144 | $57.61 $62.51 | ▼ −8.51% | ▼ −8.31% | $48.53 (+15.76%) |
Jun 11, 2026 16w ago | 144 | $56.07 $66.39 | ▼ −18.41% | ▼ −16.63% | $48.53 (+13.45%) |
Jun 10, 2026 16w ago | 144 | $54.24 $66.59 | ▼ −22.77% | ▼ −20.88% | $48.53 (+10.53%) |
Jun 8, 2026 16w ago | 144 | $51.63 $67.33 | ▼ −30.40% | ▼ −28.95% | $48.53 (+6.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access